Printed, Embossed, Grooved, Or Perforated Patents (Class 424/467)
  • Patent number: 10335379
    Abstract: The present invention relates to an oral dosage form for administration of ketamine and a method of preparing an oral dosage form for administration of ketamine, preferably once or twice a day.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: July 2, 2019
    Assignee: Develco Pharma Schweiz AG
    Inventors: Sascha Andor Manthei, Helene Rey, Marc Fischer, Olaf Mundszinger
  • Patent number: 10272048
    Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralized, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: April 30, 2019
    Assignee: Tillotts Pharma AG
    Inventors: Felipe Josè Oliveira Varum, Roberto Carlos Bravo González, Thomas Buser, Abdul Waseh Basit, Ana Cristina Freire
  • Patent number: 10117838
    Abstract: Composition for the prolonged release of trimetazidine wherein the inner phase comprises trimetazidine and the outer layer comprises a retardant and an anti-agglomerant.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: November 6, 2018
    Assignee: LES LABORATOIRES SERVIER
    Inventors: Patrick Genty, Christophe Hermelin, Jean-Manuel Pean
  • Patent number: 9943486
    Abstract: A solid tablet formed through direct compression of powder, the powder comprising meloxicam as an active ingredient and one or more excipients which are homogenously dispersed within the tablet that can be broken into two, three or four units with each unit containing equal amounts of the meloxicam.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: April 17, 2018
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Martin A. Folger, Stefan Lehner, Horst Schmitt
  • Patent number: 9326946
    Abstract: According to the present invention, a multilayer tablet showing suppressed layer separation and a production method thereof are provided. A concave portion having a depth of not less than 0.1 mm Ka is formed on at least one surface Sa of the both front and back surfaces (Sa, Sb) of a multilayer tablet. Particularly, a multilayer structure obtained by, in tableting, forming a convex portion for forming the concave portion on at least the upper punch, and preliminarily compressing all layers in the multilayer tablet with the upper punch to form a concave portion having the same shape with a depth of not less than 0.1 mm on the upper surface of all layers, wherein the powder materials of the next layer are protruding into the concave portion, is a preferable embodiment.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: May 3, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kazuki Harada, Hikaru Fukuyama, Masahiko Koike
  • Patent number: 9265732
    Abstract: The present invention is directed to dosage forms that can be used in therapeutic methods involving the oral co-administration of a combination of at least two drugs, one of which impairs gastrointestinal absorption and one of which does not. The dosage forms are designed so that the drug impairing absorption is not released into the gastrointestinal tract of a patient until after the drugs that do not impair absorption have been released and substantially absorbed. The invention may be used in treatment of migraine using a combination of triptans and NSAIDs or in the treatment of pain using a combination of NSAIDs and opioid analgesics.
    Type: Grant
    Filed: December 6, 2007
    Date of Patent: February 23, 2016
    Assignee: Pozen Inc.
    Inventors: John Plachetka, Donna Gilbert
  • Patent number: 9114072
    Abstract: A rapidly dispersing dosage form is described, which releases its active ingredients within a period of less than about ninety seconds. These dosage forms exhibit a three-dimensional shape that is retained for adequate storage but is readily dispersed in the presence of excess moisture. Also disclosed are methods of administration of a medicament and a process for the preparation of rapidly dispersing dosage forms.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: August 25, 2015
    Assignee: Massachusetts Institute of Technology
    Inventors: Jaedeok Yoo, Sandeep Kumar, Donald C. Monkhouse
  • Publication number: 20150132379
    Abstract: A dry-coated tablet 1 comprises an inner core 2 which contains an active component and an outer layer 3 which contains powdery solid components and coats the inner core 2. Openings 8c and 9c are formed in circular surfaces 2a and 2b respectively of the inner core 2, wherein each of the openings is larger than the average particle size of a component the average particle size of which is the smallest of the powdery solid components contained in the outer layer 3, and the inner surface 3a of the outer layer 3 penetrates in the openings 8c and 9c.
    Type: Application
    Filed: May 28, 2013
    Publication date: May 14, 2015
    Applicant: Takeda Pharmaceutical Company Limited
    Inventor: Tetsuya Kawano
  • Patent number: 8900632
    Abstract: Coated dosage forms comprising a tablet core, preferably in compressed form, that has a coating over its exterior surface and one or more patterns debossed in the tablet surface are disclosed. Methods for manufacturing such dosage forms are also disclosed.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: December 2, 2014
    Assignee: McNeil-PPC, Inc.
    Inventors: Joel H. Waldman, Anthony S. Bean, Fernanda Franzoi
  • Patent number: 8815288
    Abstract: Disclosed herein is an oral dosage formulation that contains both immediate-release and sustained release drugs for treating neurodegenerative disorders. The immediate-release drug in the oral dosage formulation is an acetylcholinesterase inhibitor (AChEI) with a dissolution rate of releasing more than 80% of the AChEI within 60 min; and the sustained-release drug is memantine with a dissolution rate of releasing more than 80% of memantine within 12 hours.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: August 26, 2014
    Assignee: Center Laboratories, Inc.
    Inventors: Huai-Cheng Lee, Chien-Fen Chen, Chuen-Lin Din, Rong Jin Lin
  • Patent number: 8815290
    Abstract: The present invention relates to an improved gelatinous coated dosage form having two end regions coated with gelatinous materials and an exposed circumferential band. Openings are provided in at least the exposed band to reveal the core material. The invention also relates to methods for manufacturing such gelatinous coated dosage forms.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: August 26, 2014
    Assignee: McNeil-PPC, Inc.
    Inventors: Roger A. Rinker, Nicholas J. Casale, James H. Comly, Brenda Pollock, Atul Ayer, Johan Geerke, Martin Costello, Dennis Wieand, Kishor Parekh
  • Publication number: 20140227351
    Abstract: Taste masked multi-layered particles include an inert core, one or more coating layer(s) comprising a pharmaceutically active ingredient and a binder, an intermediate coating layer (seal coating) free from a low molecular weight water-soluble ionic compound and including a water-soluble pharmaceutical film-forming compound selected from (i) HPMC and PEG or (ii) PVP, and an outer coating layer (final or taste masking coating) free from a low molecular weight water-soluble ionic compound and comprising (i) a poly(meth)acrylate or (ii) a mixture including 60-90% (w/w) EC and 10-40% (w/w) HPMC, where the pharmaceutically active ingredient is water-soluble and includes either at least one basic group and/or a bitter taste. Further disclosed are methods for the production of such particles and pharmaceutical compositions including such particles.
    Type: Application
    Filed: April 16, 2014
    Publication date: August 14, 2014
    Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBH
    Inventors: Martin FOLGER, Stefan LEHNER, Annette GRAVE, Norbet POELLINGER, Randolph SEIDLER
  • Patent number: 8802143
    Abstract: Disclosed herein is a method for treating patient suffering from a disorder related to central nervous system with an oral dosage formulation that contains both sustained-release and immediate-release drugs. The sustained-release drug in the oral dosage formulation is memantine, and the formulation provides an average blood level Cmax of the memantine in a range of about 10-24 ng/mL during an average Tmax of about 10-45 hours. The immediate-release drug in the oral dosage formulation is an acetylcholinesterase inhibitor (AChEI), and the formulation provides an average blood level Cmax of the AChEI in a range of about 12-38 ng/mL during an average Tmax of less than about 4 hours.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: August 12, 2014
    Assignee: Center Laboratories, Inc.
    Inventors: Guang-Tzuu Shane, Chien-Fen Chen, Chuen-Lin Din, Hui-Ling Tsai, Pei-Chen Tsai
  • Patent number: 8758816
    Abstract: The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: June 24, 2014
    Assignee: Meda Pharmaceuticals Inc.
    Inventors: Dennis Fuge, John Higson, Bryan A. Roecklein, Gul Balwani, Alexander D. D'Addio
  • Patent number: 8712163
    Abstract: Disclosed is a computer-implemented method of pill analysis including the steps of acquiring a pill image having an image frame and detecting contrast shifts within the image frame to locate at least one object with an object outline. A first value for the object(s) is determined, where the value is an area, a position, a length, a width, an angle, a color, a brightness, a code, a shape, a crystal pile size, a crystal geometry, a substance identity, or a character identity. Based on the first and second values, the computer outputs a result to a user.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: April 29, 2014
    Assignee: EyeNode, LLC
    Inventor: Jason Alexander Osheroff
  • Publication number: 20140112988
    Abstract: The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.
    Type: Application
    Filed: December 19, 2013
    Publication date: April 24, 2014
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: William Rowe, Patricia Hurter, Christopher Young, Kirk Dinehart, Marinus Jacobus Verwijs, Kirk Overhoff, Peter D.J. Grootenhuis, Martyn Botfield, Alfredo Grossi
  • Patent number: 8685449
    Abstract: Pharmaceutical compositions with anti-obesity activity that act peripherally are provided, which comprise a premixture made up of pure orlistat as the active ingredient and other components that afford the premixture stability and suitable physical properties for simply preparing compositions for oral use with convenient dosage flexibility; and optionally necessary thickening, flavouring and colouring agents. A method for preparing said compositions is also provided. The orlistat content in the premixture is less than 20% of the total weight of the mass, preferably between 12 and 17%. The pharmaceutical composition can be formulated indistinctively from the premixture both as grooved tablets and powder for suspension.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: April 1, 2014
    Assignees: Laboratorios Bago S.A., Eastbrand Holding GmbH
    Inventor: Mario Atilio Los
  • Publication number: 20140023708
    Abstract: According to the present invention, a multilayer tablet showing suppressed layer separation and a production method thereof are provided. A concave portion having a depth of not less than 0.1 mm Ka is formed on at least one surface Sa of the both front and back surfaces (Sa, Sb) of a multilayer tablet. Particularly, a multilayer structure obtained by, in tableting, forming a convex portion for forming the concave portion on at least the upper punch, and preliminarily compressing all layers in the multilayer tablet with the upper punch to form a concave portion having the same shape with a depth of not less than 0.1 mm on the upper surface of all layers, wherein the powder materials of the next layer are protruding into the concave portion, is a preferable embodiment.
    Type: Application
    Filed: March 2, 2012
    Publication date: January 23, 2014
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Kazuki Harada, Hikaru Fukuyama, Masahiko Koike
  • Publication number: 20130295176
    Abstract: Dividable galenical form for the modified release of active ingredient, wherein the non-subdivided galenical form and a portion of said form obtained by subdivision have identical dissolution profiles.
    Type: Application
    Filed: June 12, 2013
    Publication date: November 7, 2013
    Inventors: Gilles FONKNECHTEN, Patrick Genty, Jean-Manuel Pean, Patrick Wuthrich
  • Patent number: 8506999
    Abstract: Deeply scored pharmaceutical tablets are disclosed, along with pharmaceutical tablets with a score in a segment that adjoins a segment lacking a pharmacologically effective dose of any drug.
    Type: Grant
    Filed: December 27, 2010
    Date of Patent: August 13, 2013
    Assignee: ACCU-BREAK Technologies, Inc.
    Inventors: Lawrence Solomon, Allan S. Kaplan
  • Publication number: 20130202700
    Abstract: Coated dosage forms comprising a tablet core, preferably in compressed form, that has a coating over its exterior surface and one or more patterns debossed in the tablet surface are disclosed. Methods for manufacturing such dosage forms are also disclosed.
    Type: Application
    Filed: February 1, 2013
    Publication date: August 8, 2013
    Applicant: MCNEIL-PPC, INC.
    Inventor: MCNEIL-PPC, INC.
  • Patent number: 8498052
    Abstract: A composition including an optical substrate removably attached to an item. At least a portion of the substrate has a diffraction grating embedded therein or thereon. The grating has a resultant refractive index variation at a grating location. The grating provides an output optical signal indicative of a code when illuminated by an incident light signal.
    Type: Grant
    Filed: September 14, 2009
    Date of Patent: July 30, 2013
    Assignee: Illumina, Inc.
    Inventors: John A. Moon, Martin A. Putnam, Alan D. Kersey, David Fournier, Joseph Pinto
  • Publication number: 20120294941
    Abstract: Pharmaceutical compositions with anti-obesity activity that act peripherally are provided, which comprise a premixture made up of pure orlistat as the active ingredient and other components that afford the premixture stability and suitable physical properties for simply preparing compositions for oral use with convenient dosage flexibility; and optionally necessary thickening, flavouring and colouring agents. A method for preparing said compositions is also provided. The orlistat content in the premixture is less than 20% of the total weight of the mass, preferably between 12 and 17%. The pharmaceutical composition can be formulated indistinctively from the premixture both as grooved tablets and powder for suspension.
    Type: Application
    Filed: February 1, 2010
    Publication date: November 22, 2012
    Applicants: Eastbrand Holding GMBH, Laboratorios Bago S.A.
    Inventor: Mario Atilio Los
  • Patent number: 8231902
    Abstract: A pharmaceutical tablet adapted for accurate division of a dose of a drug into two or more smaller doses, which tablet has two or more segments.
    Type: Grant
    Filed: November 18, 2005
    Date of Patent: July 31, 2012
    Assignee: Accu-Break Technologies, Inc.
    Inventors: Lawrence Solomon, Allan S. Kaplan
  • Publication number: 20120177735
    Abstract: Disclosed herein is an oral dosage formulation that contains both immediate-release and sustained release drugs for treating neurodegenerative disorders. The immediate-release drug in the oral dosage formulation is an acetylcholinesterase inhibitor (AChEI) with a dissolution rate of releasing more than 80% of the AChEI within 60 min; and the sustained-release drug is memantine with a dissolution rate of releasing more than 80% of memantine within 12 hours.
    Type: Application
    Filed: September 29, 2010
    Publication date: July 12, 2012
    Applicant: Center Laboratories, Inc.
    Inventors: Huai-Cheng Lee, Chien-Fen Chen, Chuen-Lin Din, Rong Jin Lin
  • Patent number: 8158148
    Abstract: Accurate means of dosing with a compressed, segmented pharmaceutical tablet, and tablettes formed from said tablets, is disclosed.
    Type: Grant
    Filed: May 23, 2005
    Date of Patent: April 17, 2012
    Assignee: Accu-Break Technologies, Inc.
    Inventors: Lawrence Solomon, Allan S. Kaplan
  • Patent number: 8092833
    Abstract: The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. The invention also relates to a method of preparing a composition. The method combines a therapeutic agent, a polymer having host or guest functionality, and a complexing agent having guest or host functionality to form the therapeutic composition. The complexing agent forms an inclusion complex with the polymer. The invention also relates to a method of delivering a therapeutic agent.
    Type: Grant
    Filed: July 29, 2010
    Date of Patent: January 10, 2012
    Assignees: California Institute of Technology, Calando Pharmaceuticals, Inc.
    Inventors: Suzie Hwang Pun, Hector Gonzalez, Mark E. Davis, Nathalie C. Bellocq, Jianjun Cheng
  • Publication number: 20110300208
    Abstract: A pharmaceutical tablet adapted for accurate division of a dose of a drug into two or more smaller doses, which tablet has two or more segments.
    Type: Application
    Filed: August 15, 2011
    Publication date: December 8, 2011
    Inventors: Lawrence Solomon, Allan S. Kaplan
  • Patent number: 8034380
    Abstract: An immediate release compressed pharmaceutical tablet that has two or more segments and a top and a bottom and has a height that exceeds the width of the tablet. The height is measured vertically from the top to the bottom of the tablet while it is in the tablet die in which it is fully compressed, after compression has been completed. The width is measured as the greatest horizontal dimension of the tablet at a location halfway between the top and the bottom of the tablet, except that when the horizontal cross-section of the tablet is substantially rectangular, the width is defined by locating the two shorter sides of the perimeter of the horizontal cross-section, and measuring the length of a line that is at right angle to the shorter sides.
    Type: Grant
    Filed: May 23, 2005
    Date of Patent: October 11, 2011
    Assignee: Accu•Break Technologies, Inc.
    Inventors: Lawrence Solomon, Allan S. Kaplan
  • Patent number: 8021690
    Abstract: The present invention provides solid preparations having two or more colors or a pattern of two or more different colors which can solve the problems of the prior art including the complexity of production processes and the low strength of solid preparations. Specifically, an object of the present invention is to provide solid preparations coated with a continuous film coating layer having two or more different colors or a pattern of two or more different colors which preparations are obtained by irradiating a part of the film coating layer containing one or more colorants with light, a process for the preparation of such solid preparations, and a film coating agent therefor.
    Type: Grant
    Filed: April 26, 2001
    Date of Patent: September 20, 2011
    Assignee: Shin-Etsu Chemical Co., Ltd.
    Inventors: Hiroyasu Kokubo, Sakae Obara
  • Patent number: 7988996
    Abstract: Described is a compressed multiple layer pharmaceutical tablet that has a height that exceeds the width of the tablet. The height is measured vertically from the top to the bottom of the tablet while it is in the tablet die in which it is fully compressed, after compression has been completed. The width is measured as the greatest horizontal dimension of the tablet at a location halfway between the top and the bottom of the tablet, except that when the horizontal cross-section of the tablet is substantially rectangular, the width is defined by locating the two shorter sides of the perimeter of the horizontal cross-section, and measuring the length of a line that is at right angle to the shorter sides. The layers can form a segment or, preferably, more than one segment.
    Type: Grant
    Filed: November 21, 2006
    Date of Patent: August 2, 2011
    Assignee: Accu-Break Technologies, Inc.
    Inventors: Lawrence Solomon, Allan S. Kaplan
  • Patent number: 7985419
    Abstract: A divisible pharmaceutical tablet comprises an upper portion and a lower portion, the upper portion including at least one upper convex surface bordering at least one dividing notch. A ridgeline is formed between the at least one dividing notch and the at least one upper convex surface. The upper convex surface includes an apex defined at a location along the ridgeline.
    Type: Grant
    Filed: December 22, 2006
    Date of Patent: July 26, 2011
    Assignee: Watson Laboratories, Inc.
    Inventors: Nilesh H. Parikh, William Crawford Hite, Bhavesh R. Patel
  • Publication number: 20110171302
    Abstract: Disclosed herein is a method for treating patient suffering from a disorder related to central nervous system with an oral dosage formulation that contains both sustained-release and immediate-release drugs. The sustained-release drug in the oral dosage formulation is memantine, and the formulation provides an average blood level Cmax of the memantine in a range of about 10-24 ng/mL during an average Tmax of about 10-45 hours. The immediate-release drug in the oral dosage formulation is an acetylcholinesterase inhibitor (AChEI), and the formulation provides an average blood level Cmax of the AChEI in a range of about 12-38 ng/mL during an average Tmax of less than about 4 hours.
    Type: Application
    Filed: March 25, 2011
    Publication date: July 14, 2011
    Applicant: Center Laboratories, Inc.
    Inventors: Guang-Tzuu SHANE, Chien-Fen Chen, Chuen-Lin Din, Hui-Ling Tsai, Pei-Chen Tsai
  • Patent number: 7968123
    Abstract: The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. The invention also relates to a method of preparing a composition. The method combines a therapeutic agent, a polymer having host or guest functionality, and a complexing agent having guest or host functionality to form the therapeutic composition. The complexing agent forms an inclusion complex with the polymer. The invention also relates to a method of delivering a therapeutic agent.
    Type: Grant
    Filed: October 25, 2006
    Date of Patent: June 28, 2011
    Assignees: California Institute of Technology, Calando Pharmaceuticals, Inc.
    Inventors: Suzie Hwang Pun, Hector Gonzalez, Mark E. Davis, Nathalie C. Bellocq, Jianjun Cheng
  • Publication number: 20110033537
    Abstract: The invention relates to a sustained release formulation for delivering one or more pharmaceutically active agents. The formulation comprises cross-linked high amylose starch and at least one pharmaceutically active agent, and optionally can be subdivided into smaller dosage forms where the smaller dosage forms have substantially the same sustained release properties as the formulation from which they were derived. The formulations can provide sustained release for up to at least 24 hours, and because of their divisability permits a recipient of the active agent or the person administering the active agent to titrate the dosage of the agent.
    Type: Application
    Filed: October 15, 2010
    Publication date: February 10, 2011
    Inventors: Sonia Gervais, Damon Smith, Pauline Contamin, Rachid Ouzerourou, My Linh Ma
  • Patent number: 7883722
    Abstract: A composition for controlled delivery of at least one active substance into an aqueous medium by erosion at a preprogrammed rate of at least one surface of the composition, the composition comprising a matrix which is erodible in the aqueous medium in which the composition is to be used and which allows substantially no diffusion of water into the composition beyond any exposed surface layers of the matrix, the matrix comprising at least one substantially water soluble crystalline polymer, e.g. a polyethylene glycol, with at least one water-dispersible or water-soluble surface active agent, e.g. a non-ionic emulsifier, dispersed therein, at least one release modifier, e.g. an enteric coating material, that functions to regulate erosion of the matrix within a pH range of from about 2 to about 7, and at least one active substance. The composition provides controlled, e.g. substantially zero order, release in both the stomach and the intestines despite different conditions of pH, agitation and absorption.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: February 8, 2011
    Assignee: Egalet Ltd.
    Inventor: Daniel Bar-Shalom
  • Patent number: 7879352
    Abstract: Deeply scored pharmaceutical tablets are disclosed, along with pharmaceutical tablets with a score in a segment that adjoins a segment lacking a pharmacologically effective dose of any drug.
    Type: Grant
    Filed: May 23, 2005
    Date of Patent: February 1, 2011
    Assignee: Accu-Break Technologies, Inc.
    Inventors: Lawrence Solomon, Allan S. Kaplan
  • Publication number: 20110020447
    Abstract: The present invention relates to a novel dosage form, to a process for preparing the dosage form and to the use of the dosage form in the treatment of neurological and psychiatric disorders.
    Type: Application
    Filed: February 28, 2008
    Publication date: January 27, 2011
    Inventors: Allan James Clarke, Ian Paul Conn, Simon Richard Hicks, Yu Li, Xiaolei Wang
  • Publication number: 20100297228
    Abstract: To improve anticounterfeiting protection, a method for imprinting pharmaceutical unit compositions comprising: providing a pharmaceutical unit composition, partially coating the exterior of the composition with a coating, stamping the coating with a stamp comprising a plurality of identification features, wherein identification features from the stamp are at least partially transposed in the coating and form a barcode, wherein the plurality of identification features comprise at least one lateral dimension of about 1,000 nm or less. Other objects can be coated and stamped including currency and luxury goods.
    Type: Application
    Filed: October 29, 2008
    Publication date: November 25, 2010
    Inventors: Cedric Loiret-Bernal, Nabil Amro, Sandeep Disawal, Bjoern Rosner, John E. Bussan, Bo He
  • Patent number: 7838031
    Abstract: A method for providing partial doses of a drug or drugs is disclosed. The method includes breaking of a tablet configured to have an active layer as a first segment and an inactive support layer or substrate as a second segment, or breaking a layered tablet through a first active segment which is deeply or completely scored.
    Type: Grant
    Filed: May 25, 2006
    Date of Patent: November 23, 2010
    Inventors: Lawrence Solomon, Allan S. Kaplan
  • Publication number: 20100255082
    Abstract: Tablet and capsule formulations with a similar in vitro drug release profile for whole tablet and when broken and/or a bioequivalent drug release profile when taken whole or when broken are provided. In addition, coated splittable tablets are provided. Methods for production of these formulations and tablets and their administration are also provided.
    Type: Application
    Filed: July 24, 2009
    Publication date: October 7, 2010
    Inventors: Ishwar Chauhan, Siva Rama Krishna Nutalapati
  • Patent number: 7807197
    Abstract: A dosage form comprises at least one active ingredient, a first portion which comprises an exterior surface and one or more cavities defining at least one interior surface having indentations and an exterior surface, and a second molded portion which is inlaid into the cavities of the first portion and has an exterior surface. The first and second portions are in contact at an interface, the second portion comprises a solidified thermoplastic material, and the second portion resides substantially conformally upon the indentations of the first portion. In another embodiment, a dosage form comprises at least one active ingredient, a core having an outer surface and a shell residing on at least a portion of the core outer surface, wherein the shell comprises a first shell portion and a second molded shell portion which is inlaid into the first shell portion.
    Type: Grant
    Filed: September 28, 2002
    Date of Patent: October 5, 2010
    Assignee: McNeil-PPC, Inc.
    Inventors: Der-Yang Lee, Harry S. Sowden, Martin Thomas
  • Patent number: 7807198
    Abstract: The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. The invention also relates to a method of preparing a composition. The method combines a therapeutic agent, a polymer having host or guest functionality, and a complexing agent having guest or host functionality to form the therapeutic composition. The complexing agent forms an inclusion complex with the polymer. The invention also relates to a method of delivering a therapeutic agent.
    Type: Grant
    Filed: December 28, 2005
    Date of Patent: October 5, 2010
    Assignees: California Institute of Technology, Calando Pharmaceuticals, Inc.
    Inventors: Suzie Hwang Pun, Hector Gonzalez, Mark E. Davis, Nathalie C. Bellocq, Jianjun Cheng
  • Publication number: 20100239668
    Abstract: Described is a layered or segmented controlled release pharmaceutical tablet adapted for separating one segment from another by breaking through a segment.
    Type: Application
    Filed: June 19, 2007
    Publication date: September 23, 2010
    Inventors: Allan S. Kaplan, Lawrence Solomon
  • Publication number: 20100226980
    Abstract: A subject of the invention is a tablet for pharmaceutical use, particularly for veterinary use, particularly suitable for the chronic treatment of hepatic insufficiency, comprising at least one S-Adenosyl-Methionine salt. Said tablet has the advantage of being divisible and being capable of including an appetizing agent.
    Type: Application
    Filed: January 8, 2010
    Publication date: September 9, 2010
    Applicant: VETOQUINOL
    Inventor: Marinette MOREAU
  • Patent number: 7780985
    Abstract: The invention provides a novel “separation marking” on a tablet as a means for assisting in the identification of a region on the tablet that is desired to be able to be broken from time to time. Said breaking allows production of smaller dosage forms known herein as tablettes. In a preferred embodiment, the separation mark will be a printed mark that is made on the tablet surface.
    Type: Grant
    Filed: July 12, 2005
    Date of Patent: August 24, 2010
    Assignee: Accu-Break Technologies, Inc.
    Inventors: Lawrence Solomon, Allan S. Kaplan
  • Publication number: 20100143467
    Abstract: A tablet (4) for pharmaceutical use has on at least one part of its surface a diffractive microstructure (11) which generates diffraction effects which can be perceived in the visible spectral range and which serve as visual safety feature. The tablet (4) consists of a plurality of individual powder particles, where the diffractive microstructures (11) are impressed into the surface of the individual powder particles. A compression tool (1, 1a, 1b, 3) to produce such tablets (4) has on one pressing surface of the compression tool (1, 1a, 1b, 3) micro-structures (11), where said microstructures (11) have dimensions which are smaller than the dimensions of the individual crystallites (30) of the material of the pressing surface of the compression tool (1, 1a, 1b, 3). The micro-structures (11) of the compression tool can be produced for example by ion etching or by imprinting.
    Type: Application
    Filed: June 12, 2007
    Publication date: June 10, 2010
    Inventors: Alexander Stuck, Harald Walter, Marc Schnieper, Jürgen Sôchtig, Christian Zschokke
  • Publication number: 20100086591
    Abstract: The invention provides a rapidly disintegrating dosage form comprising a partially-coated tablet having at least one elongated groove along its surface, such that a portion of the at least one elongated groove extends beneath the coating.
    Type: Application
    Filed: September 7, 2007
    Publication date: April 8, 2010
    Inventors: Dennis C. Murachanian, John R. Kirk
  • Publication number: 20100074949
    Abstract: The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.
    Type: Application
    Filed: August 13, 2009
    Publication date: March 25, 2010
    Inventors: William Rowe, Patricia Hurter, Christopher Young, Kirk Dinehart, Marinus Jacobus Verwijs, Kirk Overhoff, Peter D.J. Grootenhuis, Martyn Botfield, Alfredo Grossi
  • Publication number: 20090324715
    Abstract: The present invention relates to high dose oral pharmaceutical compositions of artemether and lumefantrine, and process for preparation thereof. The compositions comprise of artemether and lumefantrine comprising artemether in an amount of from about 40 mg to about 80 mg, lumefantrine in an amount of from about 240 mg to about 480 mg. The compositions are useful for treatment of uncomplicated infections with Plasmodium falciparum, including strains from multi-drug-resistant areas.
    Type: Application
    Filed: June 22, 2007
    Publication date: December 31, 2009
    Inventors: Sumit Madan, Vikas Batra, Arno Appavoo Enose, Vinod Arora